Sichenzia Ross Friedman Ference LLP Represents Amarantus BioScience Holdings, Inc. in $5.5M Registered Direct Offering and Private Placement
October 1, 2015 — New York, NY – Press Release – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP (“SRFF”) is pleased to announce that the Firm has represented Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing therapeutic and diagnostic product candidates for orphan indications and neurology in a registered direct offering where Amarantus issued $2.75 million of newly designated Series H convertible preferred stock and warrants. Additionally, SRFF represented Amarantus in a concurrent private placement where the Company issued $2.75 million in secured debt and warrants. At closing, the Company simultaneously repurchased all of the remaining 1,260 outstanding Series G convertible shares, having a face value of $6,300,000, and 212,087 common shares held by Discover Growth Fund at closing, for a total of $4.75 million in cash.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey Fessler and Marcelle Balcombe.